Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Statin myotoxicity: a review of genetic susceptibility factors.

Neuromuscular disorders : NMD - 1 Jan 2014

Needham M, Mastaglia F L

Abstract excerpt

The 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors (statins) are among the most common medications prescribed worldwide, but their efficacy and toxicity vary between individuals. One of the major factors contributing to intolerance and non-compliance are the muscle side-effects, which range from mild myalgia through to severe life-threatening rhabdomyolysis. One way to address this is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscular Diseases

Share to Pharmacogenetics

Share to Risk Factors

Source

Identifiers

PMID: 24176465
DOI: 10.1016/j.nmd.2013.09.011

Genes

COQ2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Statin myotoxicity: a review of genetic susceptibility factors.PMID 24176465Read ↗

The genetics of statin-induced myopathy.Semantic proximity Read ↗

Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.Semantic proximity Read ↗

Statin-associated myopathy: from genetic predisposition to clinical management.Semantic proximity Read ↗

Genetic predisposition to statin myopathy.Semantic proximity Read ↗

Pharmacogenetics of Statin-Induced MyotoxicitySemantic proximity Read ↗

Pharmacogenomic insights into treatment and management of statin-induced myopathySemantic proximity Read ↗

Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle ComponentsSemantic proximity Read ↗

Approach to clinical and genetic characterization of statin-induced myopathy.Semantic proximity Read ↗

Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.Semantic proximity Read ↗

Statin-associated muscle toxicity : clinical and genomic perspectivesSemantic proximity Read ↗

Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence.Semantic proximity Read ↗

The Association between Genetic Polymorphisms and Simvastatin-Induced Myopathy: A Narrative Synthesis of Evidence.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.